Compare Neurocrine Biosciences Inc (NBIX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs TKO Group Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while TKO Group Holdings Inc trades at $178.01 (market cap $13.28B). The key difference: Neurocrine Biosciences Inc and TKO Group Holdings Inc are close in size by market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and TKO Group Holdings Inc for 30 Days on average.
| NBIX | TKO | |
|---|---|---|
Market Cap | $14.36B | $13.28B |
Volume | 1,237,180 | 857,653 |
Sector | Health | Media |
52-Week High | $185.50 | $224.96 |
52-Week Low | $123.10 | $175.58 |
Typical Hold Time | 23 Days | 30 Days |
Enterprise Value | $14.37B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
TKO trades at $181.63, up 1.67% today, but technical indicators signal a bearish trend with the stock near support at $180. Fundamentally, the company shows revenue growth with 2026 revenue projected at $5.3B and net income of $230M, though its high P/E of 63.73 indicates premium valuation. Recent Q2 2026 earnings missed expectations, but the company raised full-year guidance, reflecting operational strength. A dividend of $0.79 is scheduled for payment on September 30, 2026, adding income appeal.
The outlook for TKO is mixed; strong analyst buy consensus (89.47%) and a $227 price target suggest 25% upside, driven by media rights and live events. However, risks include competitive pressures, earnings volatility, and the stock's bearish technical posture. Investors should weigh solid fundamentals against near-term price weakness and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
